MAX - SHOCK Clinical Trial
Recruiting now NCT06556667
Run by Ottawa Heart Institute Research Corporation · for 18 and older · All sexes
What this study is about
Can Electrical Cardioversion (ECV) for AF be improved. It is the preferred method to restore sinus rhythm in patients with AF in whom a rhythm-control strategy is pursued. Hypothesis: ECV success rates will be greater with a biphasic defibrillator with maximum energy of 360J (® Physio-Control) compared to a biphasic defibrillator with maximum energy of 200J (® Zoll)
Who can join (things the study team will check)
✅ You may be able to join if…
- Patients age > 18 years.
- Persistent atrial fibrillation.
- Scheduled for elective cardioversion at UOHI
- Patient is within the circle of care of UOHI Electrophysiology staff
🚫 You may not be able to join if…
- Known left-atrial appendage thrombus.
- Contraindication to appropriate anticoagulation.
- Patient is included in another randomized clinical trial.
- Patient does not meet all of the above listed inclusion criteria.
Where this trial is running
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Who to contact
Tammy Knight · 613-696-7000 · tknight@ottawaheart.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06556667.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.